ArticleWorld journal of surgical oncology2026
Targeting lncRNA RP11-358L4.1 attenuates breast cancer cell proliferation and is associated with cell cycle and immune-related transcriptomic signatures.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundBreast cancer (BC) is a leading cause of morbidity and mortality in women, with metastasis and recurrence being major determinants of poor prognosis. Long non-coding RNAs (lncRNAs) have emerged as important regulators in cancer biology, but the role of RP11-358L4.1 in BC progression and chemotherapeutic response remains unclear.
methodsRP11-358L4.1 expression was measured in 25 paired BC and adjacent normal tissues. Functional assays following RP11-358L4.1 knockdown in MCF-7 and BT-474 cells assessed proliferation, apoptosis, migration, and carboplatin sensitivity. Expression of cell cycle regulators CDK1, CDK2, and p21 was evaluated. Transcriptomic sequencing, integrated with GEO datasets, was used to identify downstream targets, followed by gene set enrichment and immune infiltration analyses. Kaplan-Meier survival analysis determined prognostic relevance.
resultsRP11-358L4.1 was upregulated in breast cancer tissues and cell lines. RP11-358L4.1 knockdown suppressed proliferation and migration, increased apoptosis, and induced G0/G1 arrest in MCF-7 and BT-474 cells. RNA-seq and integrated transcriptomic analyses nominated CXCL11 and KLF2 as candidate genes associated with RP11-358L4.1-related transcriptional patterns, with enrichment results suggesting immune- and cell-cycle-related signatures. Immune-cell deconvolution further suggested differences in estimated immune infiltration across groups. In survival analyses, higher CXCL11 expression was associated with worse distant metastasis-free survival and showed a trend toward poorer overall survival, whereas higher KLF2 expression was associated with better outcomes.
conclusionRP11-358L4.1 is associated with aggressive cellular phenotypes and platinum response in vitro. CXCL11 and KLF2 represent candidate correlates linked to RP11-358L4.1 associated transcriptional signatures, providing testable hypotheses for future mechanistic and clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.